Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus on the lung cancer management after third-generation EGFR-TKI resistance.
Zhou Q, Zhao H, Lu S, Cheng Y, Liu Y, Zhao M, Yu Z, Hu C, Zhang L, Yang F, Zhao J, Guo R, Ma R, Du Y, Dong X, Cui J, Tan DSW, Ahn MJ, Tsuboi M, Maggie Liu SY, Mok TS, Wu YL. Zhou Q, et al. Among authors: wu yl. Lancet Reg Health West Pac. 2024 Dec 11;53:101260. doi: 10.1016/j.lanwpc.2024.101260. eCollection 2024 Dec. Lancet Reg Health West Pac. 2024. PMID: 39759798 Free PMC article. Review.
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection.
Dong S, Yan B, Liu SY, Gao X, Hong HZ, Li HJ, Gao W, Yan HH, Maggie Liu SY, Tu HY, Pan Y, Zhou Q, Yang XN, Xia XF, Yi X, Zhong WZ, Wu YL, Zhang JT. Dong S, et al. Among authors: wu yl. JTO Clin Res Rep. 2024 Nov 2;6(1):100758. doi: 10.1016/j.jtocrr.2024.100758. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39758595 Free PMC article.
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
Chen HJ, Tu HY, Hu Y, Fan Y, Wu G, Cang S, Yang Y, Yang N, Ma R, Jin G, Xu X, Liu A, Tang S, Cheng Y, Yu Y, Xu CR, Zhou Q, Wu YL. Chen HJ, et al. Among authors: wu yl. J Hematol Oncol. 2025 Jan 5;18(1):3. doi: 10.1186/s13045-024-01656-0. J Hematol Oncol. 2025. PMID: 39757186 Free PMC article. Clinical Trial.
A new biflavanol from bark of Nothotsuga longibracteata.
Wu YL, Dong MJ, Sun CX, Zhang MS, Xiao SJ. Wu YL, et al. J Asian Nat Prod Res. 2025 Jan 1:1-7. doi: 10.1080/10286020.2024.2446282. Online ahead of print. J Asian Nat Prod Res. 2025. PMID: 39742459
Novel Naphthyridones Targeting Pannexin 1 for Colitis Management.
Hsueh WY, Wu YL, Weng MT, Liu SY, Santavanond JP, Liu YC, Lin CI, Lai CN, Lu YR, Hsu JY, Gao HY, Lee JC, Wei SC, Lyu PC, Poon IKH, Hsieh HP, Chiu YH. Hsueh WY, et al. Among authors: wu yl. Adv Sci (Weinh). 2024 Dec 30:e2411538. doi: 10.1002/advs.202411538. Online ahead of print. Adv Sci (Weinh). 2024. PMID: 39739600
2,374 results